This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Akshay Vaishnaw
President, Research & Development at Alnylam Pharmaceuticals


Dr. Vaishnaw joined Alnylam Pharmaceuticals Inc. in 2006 as VP Clinical Research and has then subsequently served in various R&D roles with increasing responsibility. Akshay is currently the President of R&D. At Alnylam he leads the discovery and development of their pipeline of RNAi therapeutics, which includes the recently approved compound, Onpattro for hATTR amyloidosis with peripheral neuropathy. Prior to 2006, he was at Biogen as Senior Director, Translational Medicine. In his seven years at Biogen Akshay was involved in many aspects of clinical research and business development, and led the effort for the approval of alefacept (Amevive™) for chronic plaque psoriasis. Akshay received his M.D. from the University of Wales College of Medicine, U.K., and Ph.D. from the University of London, U.K., in Molecular Immunology. He is a Fellow of the Royal College of Physicians, U.K. Akshay is a member of the Board of Directors for Editas Medicine Inc. and Scholar Rock Inc. From 2014-2018, he served as a Board member of Visterra Inc.

Akshay Vaishnaw's Network

Agenda Sessions

  • The coming of age of RNA Medicines - Hilton Union Square


Speakers at this event